Research affirms consumers find CTV ads more relevant as DeepIntent enhances unique audience targeting and campaign optimization capabilities with viewership data from 30+ million LG smart TVs
NEW YORK, June 1, 2022 — DeepIntent, the leading healthcare advertising technology company built to influence patient health and business outcomes, today revealed new research that unveils insight into consumer behaviors and preferences for ad-supported content. Specifically, the research showed that 64% of connected TV (CTV) watchers prefer to see ads than pay more for content, explaining the growth of ad-supported streaming services over the past year.
Surveying more than 2,900 U.S. adults with LG smart televisions on their self-reported viewing habits and comparing those findings with real-world viewer data using automated content recognition (ACR) technology, the research indicates audiences stream content more than they realize.
Developed in partnership with LG Ads Solutions, the exclusive provider of LG smart TV native ads and audience targeting data, the study found that 96% of linear TV viewers say they watch their favorite shows exclusively via cable or satellite box. However, real-world data from their TV sets showed that only 48% of their viewership actually took place via a cable or satellite box – meaning that more than half of viewers may be watching CTV content without even realizing it.
This key finding points to the importance of using ACR data when planning, measuring, and optimizing advertising campaigns across linear and CTV. To address this value, DeepIntent today announced its complete integration with LG Ads Solutions’ real-time ACR data repository covering more than 30 million LG smart TVs in the United States. DeepIntent is the first and only demand side platform (DSP) with this capability, offering healthcare marketers unparalleled targeting capabilities for all digital formats, including CTV, desktop, and mobile.
“For too long, healthcare marketers have struggled to reach relevant audiences at scale. By combining the targeting power of CTV with ACR data, DeepIntent’s patented technology optimizes campaign audience quality and script performance in real-time,” said DeepIntent Senior Vice President of Analytics John Mangano. “Consumer research has proven that this combination influences patient outcomes.”
Conducted between March 25 and 31, additional key findings from the research include:
- 65% say targeted ads improve their experience
- 57% say CTV ads are more relevant than linear TV ads
- 42% rate the relevance of the pharma ads they see as poor or very poor
- 30% of people feel pharma ads provide helpful information to someone in their household and 27% have spoken to a doctor about a medical treatment after learning about it through an ad
These findings also reinforce past research conducted by DeepIntent that found a relationship between consumer advertising and patient research of their treatment options, which patients state as the most common factor influencing their medication adherence.
“At DeepIntent, we believe that it’s possible to measurably improve patient outcomes by arming consumers and providers alike with the information they need to know about suitable treatment options. That is why we continue to invest in research to help healthcare marketers understand what motivates patients toward healthier futures while leading the market with innovations like ACR data to make campaigns easier to plan, manage, and measure,” said Marcella Milliet Sciorra, CMO of DeepIntent.
The company’s full report on its research with LG Ads Solutions is available here.
“Understanding the efficacy of programs is about measuring as much of a campaign as we can to have a holistic view. ACR data is fantastic in terms of allowing us to understand exposure in a way that we couldn’t from a set-top box,” said AJ Kintner, Vice President of Sales at LG Ads Solutions during DeepIntent’s recent “Innovating with Intent” summit.
“As Connected TV penetration increases and television viewership becomes even more fragmented between ad-supported platforms and providers, it’s important for brands to understand where their audiences are going for content if they want to maximize the reach and efficiency of their television campaigns,” said David DeSimone, Director of Video Investment at Klick Health. “We’re working with DeepIntent to help our clients identify audience overlap between linear TV and CTV, prove CTV efficiency by measuring the cost of verified patient reach, and ultimately, enhance the reach of their campaigns.”
DeepIntent’s unique and innovative integration with LG Ad Solutions’ ACR data reflects the company’s role as a leader at the forefront of pharma’s fast-growing adoption of programmatic advertising, including CTV. LG is the second-largest manufacturer of smart televisions in the world, and DeepIntent is LG’s exclusive healthcare DSP, making it the only platform that healthcare marketers can use to purchase ads on LG’s owned-and-operated inventory in the United States. Additionally, LG Ad Solutions viewership segments are now available on DeepIntent’s Audience Marketplace.
Visit DeepIntent’s website to learn more about its advanced CTV capabilities.
DeepIntent is leading the healthcare advertising industry with data-driven solutions built for the future. Built purposefully for healthcare marketers, DeepIntent’s platform is proven to drive higher audience quality and script performance. It enables marketers to plan, activate, measure, and optimize their campaigns all within a single platform. Conceived by former Memorial Sloan Kettering data scientists, DeepIntent empowers nine of the top ten pharmaceutical companies and the leading healthcare advertising agencies to improve patient outcomes through the artful use of advertising, data science, and real-world health data. For more information, visit DeepIntent.com or find us on Twitter, Facebook, or LinkedIn.
Finn Partners for DeepIntent